Business Wire

P.I.-WORKS

22.10.2020 10:02:06 CEST | Business Wire | Press release

Share
P.I. Works Unveils Major Corporate Rebrand

In occasion of its fifteenth anniversary, P.I. Works today revealed a company-wide rebranding, including a major upgrade to its current product portfolio. The rebrand reflects the evolution of the solution capabilities and its vision as a dynamic and leading vendor in the industry.

As part of the rebrand, the company has embarked on a revamp of its official webpage, www.piworks.net and an extensive transformation of its entire product portfolio, now featuring new capabilities including enhanced customer-centric automation, automation beyond radio network, open architecture and AI-based automation tools.

The announcement also saw the renaming of the company’s popular product family, uSON to the P.I. Works EVO PlatformTM . Synonymous with EVOlution, the new identity is aimed at representing the company’s vision to drive the zero-touch evolution of mobile networks.

Thanks to its scalable architecture and easily accessible Open APIs, the suite provides operators with utmost interoperability and flexibility by circumventing vendor-lock-in and empowering operators to develop their own automation use-cases. The platform also features advanced automation, network management and data correlation capabilities.

Lineup of complementary products that run on the P.I. Works EVO Platform:

  • EXA , abbreviated from Extreme Automation, provides multi-vendor automation capabilities for all network technologies.
  • VantagePM, a vendor agnostic and no-code, end-to-end network performance management solution, with interactive dashboards and anomaly detection functionalities.
  • Experia , a customer experience and service quality monitoring solution, equipped with a highly precise geolocation engine.
  • SmartPlan , an AI-based network design and planning solution, enabling multi-dimensional investment planning.
  • Configurex , an automated parameter configuration and on-demand network audit solution.
  • Inspection , a scalable network tuning, troubleshooting and optimization solution.

Başar Akpınar, CEO and Co-Founder of P.I. Works, said “Our fifteenth year anniversary marks an important milestone in the history of both our company and the industry. The rebranding of our corporate identity and the P.I. Works EVO Platform have set us on the frontier of telecoms innovation, with an upgraded product portfolio capable of performing the most complex and sophisticated of network operations, effectively, efficiently and effortlessly.”

Djakhongir Siradjev, Engineering Director at P.I. Works, said “With the P.I. Works EVO Platform, OpenRAN and OEM vendor technologies for any network can be easily and effectively managed; enabling traditional and next-generation network technologies to co-exist, and accelerating the evolution of mobile networks.”

Link:

ClickThru

Social Media:

https://www.facebook.com/PIWorksInc/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.

Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release

Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye